Swedish bioprinting startup Fluicell made a big break into the bioprinting market in 2019 with the launch of its Biopixlar system, capable of 2D and 3D printing. Now, over a year since the initial launch, the company is still developing its technology to advance its viability for therapeutic applications. Specifically, Fluicell is focused on creating advanced therapy medicinal products (ATMP) to be used to treat various diseases and conditions. To support ongoing advancements, the company has launched a partnership program, BioRej Advance, which will bring together players from the pharmaceutical industry and academia.
The Biopixlar is a high-resolution, scalable platform based on Fluicell’s proprietary microfluidic bioprinting technology. The system also comprises a specialized software program and a gamepad interface. Fluicell believes its technology could help develop treatments for certain conditions which have been challenging to treat using more conventional methods. For instance, Biopixlar could be used to produce engineered tissue products for cardiac repair or to treat diabetes or macular degeneration.
To achieve the goal of developing bioprinted tissues and therapeutics, Fluicell has a three-phase plan, beginning with the expansion of its current activities developing human in vitro tissue models for research. The second phase will include in vivo preclinical studies, and the third phase will consist of testing the engineered tissue in clinical trials.
“This is a historical and very exciting moment for Fluicell,” said Victoire Viannay, CEO of Fluicell. “We now take the first step to fully realize the potential inherent in the Biopixlar platform. Our ongoing R&D activities have shown a clear path forward and we now accelerate our efforts to establish Fluicell as an innovation leader within regenerative medicine therapeutics.”
The BioRej Advance partnership program will further enable Fluicell to realize its ambitions by bringing together players from academia and the pharmaceutical industry. The work will draw on Fluicell’s existing R&D, which has focused on demonstrating Biopixlar’s ability to recreate biological tissues by printing them on transplantable membranes. These membranes can then be used for research purposes or for therapeutic applications, like as a tissue patch for restoring organ function.